Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001181431-10-030519
Filing Date
2010-06-01
Accepted
2010-06-01 18:08:40
Documents
2
Period of Report
2010-05-27

Document Format Files

Seq Description Document Type Size
1 FORM 3 - KLASSEN rrd277435.html 3  
1 FORM 3 - KLASSEN rrd277435.xml 3 5441
2 POWER OF ATTORNEY rrd248582_280596.htm EX-24.1 3292
  Complete submission text file 0001181431-10-030519.txt   10529
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Issuer) CIK: 0001382911 (see all company filings)

EIN.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 3344 N. TORREY PINES COURT, SUITE 200 LA JOLLA CA 92037
Business Address
Klassen Preston (Reporting) CIK: 0001493056 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33415 | Film No.: 10870911